Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (122 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chronicgreaterequal toor equalplacebo
  Phrases that lowered it: skinmmtopicaldermatitisatopic
• Sponsor's past termination rate: 3.8% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 87 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 15.6% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 741 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 91.7% (raises risk) · Drug's FDA history
• Maximum age: 85 (lowers risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports before start: 16683 (raises risk) · Drug's FDA history
• Minimum age: 0.5 (lowers risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment NCT03637400 · started 2018 · scored riskier than 67% of active trials completed
• Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus STOP MRSA NCT00729937 · started 2009 · scored riskier than 34% of active trials completed
• A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs NCT00828971 · started 2008 · scored riskier than 43% of active trials completed
• Safety, Potential Efficacy, and Pharmacokinetics of PZ-601 in the Treatment of Complicated Skin and Skin Structure Infection NCT00671580 · started 2008 · scored riskier than 74% of active trials completed
• Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA NCT02814916 · started 2017 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.